Clinical reference Biomarker Directory
Back to directory

JAK2

Established

JAK2 V617F is the molecular hallmark of classic myeloproliferative neoplasms, central to current WHO diagnostic criteria.

Also known as JAK2 JAK2 V617F Janus kinase 2
In plain language

JAK2 is a signaling protein, and one specific mutation in it is found in the vast majority of a group of blood disorders that cause overproduction of blood cells. Discovering this mutation dramatically simplified how these conditions are diagnosed, replacing older, more cumbersome diagnostic approaches.

Biomarker & context

JAK2 is a tyrosine kinase central to cytokine receptor signaling; the V617F point mutation causes constitutive activation and is the molecular hallmark of the classic BCR-ABL1-negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis).

What it indicates

JAK2 V617F is found in over 95% of polycythemia vera cases and roughly 50-60% of essential thrombocythemia and primary myelofibrosis cases; JAK2 exon 12 mutations account for most of the remaining V617F-negative polycythemia vera cases.

Diagnosis & clinical testing

Detected via PCR-based mutation testing or NGS panel on peripheral blood; current WHO diagnostic criteria for polycythemia vera require elevated hemoglobin/hematocrit plus either JAK2 V617F (or exon 12 mutation) as a major criterion, substantially simplifying diagnosis compared to the older, more cumbersome criteria that predated the mutation's discovery.

Guiding treatment

JAK2 V617F allele burden and neutrophil count help stratify thrombosis risk in myeloproliferative neoplasms; JAK inhibitors (ruxolitinib and others) are used for symptom control and spleen reduction in myelofibrosis and for polycythemia vera patients intolerant of or resistant to standard therapy.

Clinical significance

Also guides thrombosis risk stratification and JAK-inhibitor treatment decisions in myelofibrosis and polycythemia vera.

References
  1. PMC. (2010). JAK2 V617F and the evolving paradigm of polycythemia vera.
  2. PubMed. (2024). Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.